P-107 Efficacy of 2nd-line ramucirumab (RAM) plus FOLFIRI for RAS wild-type metastatic colorectal cancer (mCRC) by prior regimen: Subgroup analysis of the JACCRO CC-16

This article has no abstract
Epistemonikos ID: 17aacead2f1850a9f9fa4b06f93d92447bdff4db
First added on: Feb 14, 2025